IDXX · IDEXX Laboratories, Inc.
$551.502026-07-21Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$316
-42.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($238 · $344) Analysts Range ($640 · $800) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $3.7B | — | 31.8% | 20.4% | $927MM | −$234MM | $693MM | 10.7% | — | 35.0% | $2.6B | $10.47 | — |
| 2024.Q4 | $3.7B | 0.0% | 31.8% | 20.0% | $932MM | −$277MM | $655MM | 11.9% | — | 34.8% | $2.7B | $10.47 | — |
| 2025.Q1 | $3.9B | 6.5% | 30.7% | 20.4% | $954MM | −$185MM | $769MM | 11.4% | — | 34.4% | $2.8B | $11.01 | — |
| 2025.Q4 | $3.9B | 0.0% | 30.7% | 20.0% | $959MM | −$145MM | $814MM | 12.1% | — | 32.9% | $3.0B | $11.01 | — |
| 2026.Q1 | $4.4B | 14.1% | 33.6% | 20.0% | $1.2B | −$186MM | $1.0B | 11.2% | — | 39.6% | $3.0B | $13.58 | 29.8 |
| italics below = DCF projection · 10yr Rev CAGR: 9.1% |
| 2027.Q1 | $4.8B | +8.4% | 33.7% | 20.0% | $1.3B | −$212MM | $1.1B | 9.7% | $991MM | 41.3% | $3.2B | $15.16 | 36.4 |
| 2028.Q1 | $5.2B | +8.9% | 33.7% | 20.0% | $1.4B | −$257MM | $1.2B | 9.6% | $963MM | 41.9% | $3.5B | $16.51 | 33.4 |
| 2029.Q1 | $5.7B | +9.3% | 33.7% | 20.0% | $1.5B | −$313MM | $1.2B | 9.4% | $937MM | 42.2% | $3.8B | $18.04 | 30.6 |
| 2030.Q1 | $6.4B | +11.0% | 33.7% | 20.0% | $1.7B | −$332MM | $1.4B | 9.3% | $962MM | 43.0% | $4.2B | $20.02 | 27.5 |
| 2031.Q1 | $7.2B | +13.7% | 33.7% | 20.0% | $2.0B | −$490MM | $1.5B | 9.2% | $930MM | 44.4% | $4.6B | $22.77 | 24.2 |
|
| Term. Yr+ | $11.0B | 4.1% | 24.7% | 20.0% | $2.2B | −$378MM | $1.8B | 8.6% | $16.6B | 23.6% | — | — | — |
Active scenario IV: $316 (-42.6% vs market)